비교리스트

 카트 문의
시장보고서
상품코드
1446526

재조합 단백질 치료제 CDMO 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 공급원별, 적응증별, 지역별, 부문별 예측(2024-2030년)

Recombinant Protein Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Growth Hormones, Interferons, Vaccines, Immunostimulating Agents, Others), By Source, By Indication, By Region, And Segment Forecasts, 2024 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 173 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

재조합 단백질 치료제 CDMO 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 재조합 단백질 치료제 CDMO 시장은 2030년까지 520억 달러에 달할 것으로 예상되며, 2024년부터 2030년까지 연평균 13.95%의 성장률을 나타낼 것으로 예측됩니다.

신규 재조합 단백질 치료제 개발에 대한 기술 혁신 증가와 생물학적 제제 연구개발 증가는 재조합 단백질 치료제 CDMO 산업에 긍정적인 영향을 미칠 것으로 예상됩니다. 새로운 재조합 단백질 치료제 개발은 다양한 기술 혁신으로 인해 상당한 진전을 이루고 있습니다.

재조합 단백질은 원하는 단백질을 암호화하는 유전자를 숙주 세포(일반적으로 미생물 또는 포유류 세포)에 도입하여 원하는 단백질을 발현 및 생산함으로써 제조되는 생물공학 단백질입니다. 현재 여러 단백질 공학 플랫폼 기술이 새로운 단백질 치료제의 정확성과 기능성을 목표로 순환 반감기를 개선하기 위해 채택되고 있습니다. 이러한 기술은 또한 생산량을 늘리고 제품의 순도를 보장하는 것을 목표로 하고 있습니다.

또한, 바이오의약품 산업은 재조합 단백질을 포함한 생물학적 제제 연구개발에 투자하는 기업이 증가하면서 괄목할 만한 성장을 보이고 있습니다. 이러한 성장은 일회용 바이오리액터 및 기타 혁신적인 제조 방법의 채택과 같은 제조 기술의 발전으로 인해 촉진되고 있습니다. 예를 들어, 2024년 1월 Eurofins CDMO Alphora, Inc.는 파일럿 규모의 생물학적 제제 개발 시설을 완공했다고 발표했습니다. 이 시설은 3,300평방피트 규모로, 단클론항체(mAbs) 및 기타 포유류 유래 치료용 단백질의 개발 및 스케일업에 특화된 시설입니다.

또한, 암, 자가면역질환, 대사성 질환과 같은 만성 및 복합질환 증가로 인해 혁신적이고 효과적인 치료 옵션에 대한 수요가 증가하고 있습니다. 재조합 단백질 치료제는 이러한 복잡한 질병을 치료할 수 있는 다양한 후보를 제공합니다. 예를 들어, 미국 암 협회의 추정에 따르면, 2023년 미국에서 약 195만8310명의 신규 암 환자가 발생하고 60만9820명이 암으로 사망할 것으로 예상됩니다. 또한, 옥스포드 대학이 발표한 연구 논문에 따르면 2022년 6월에 승인 및 출시된 항체 치료제의 수는 162개에 달하며, 이 중 절반(42.6%)이 암 치료제로 개발되었습니다.

2023년 3월 미국 FDA는 Insight Corporation의 retifanlimab-dlwr을 전이성 또는 재발성 국소 진행성 메르켈세포암(MCC) 성인 환자 치료제로 조기 승인했습니다. 또한, 암의 생물학적 치료는 면역 반응의 회복, 자극 및 강화를 지원합니다. 따라서 많은 제약 및 바이오 기업들이 암과 관련된 새로운 치료법에 대한 투자를 아끼지 않고 있습니다. 이러한 발전은 총체적으로 더 많은 고품질 제품을 생산하는 것을 목표로 하고 있습니다.

재조합 단백질 치료제 CDMO 시장 보고서 - 주요내용

  • 2023년 기타 부문이 시장을 주도할 것으로 예상됩니다. 이 부문의 성장을 주도하는 것은 혈장 유래 제품보다 안전한 대안으로 재조합 단백질 요법이 증가하고 있으며, 이는 감염성 질환의 혈액 감염을 감소시킬 수 있기 때문입니다.
  • 공급원을 기준으로 포유류 시스템이 2023년 67.4%의 가장 큰 시장 점유율을 차지했습니다. 이는 재조합 단백질공급원으로 포유류 시스템의 채택이 증가했기 때문입니다. 포유류 세포 배양 시스템은 적절한 번역 후 변형으로 복잡한 단백질을 생산하는 데 유리하며 광범위한 치료 용도에 적합합니다.
  • 적응증별로 보면, 2023년 대사성 질환 분야가 21.8% 시장 점유율을 차지할 것으로 예상됩니다. 이 분야는 고령화 사회의 발전과 제약 산업의 활발한 수요에 의해 주도되고 있으며, 이는 이 분야의 번영에 기여하고 있습니다.
  • 북미는 2023년 38.5%의 점유율로 시장을 장악했습니다. 이 지역은 강력한 R&D 인프라와 탄탄한 바이오의약품 산업을 보유하고 있어 시장 성장에 기여하고 있습니다. 또한 미국은 재조합 단백질 치료제를 포함한 바이오 의약품 제조 인프라가 고도로 발달되어 있습니다.

목차

제1장 조사 방법과 범위

제2장 제2장 주요 요약

  • 시장 현황
  • 부문 현황
  • 경쟁 구도 현황

제3장 재조합 단백질 치료제 CDMO 시장 : 변수, 동향, 범위

  • 시장 계통 전망
  • 재조합 단백질 치료제 CDMO 시장 역학
  • 재조합 단백질 치료제 CDMO 시장 : 분석 툴
  • COVID-19가 재조합 단백질 치료제 CDMO 시장에 미치는 영향
  • COVID-19의 바이오프로세스와 아웃소싱에 대한 영향

제4장 재조합 단백질 치료제 CDMO 시장 : 유형 추정·동향 분석

  • 정의와 범위
  • 부문 대시보드
  • 세계의 재조합 단백질 치료제 CDMO 시장변수 분석
  • 세계의 재조합 단백질 치료제 CDMO 시장 규모와 동향 분석, 유형별, 2018-2030년

제5장 재조합 단백질 치료제 CDMO 시장 : 소스 추정·동향 분석

  • 정의와 범위
  • 부문 대시보드
  • 세계의 재조합 단백질 치료제 CDMO 시장변수 분석
  • 세계의 재조합 단백질 치료제 CDMO 시장 규모와 동향 분석, 소스별, 2018-2030년

제6장 재조합 단백질 치료제 CDMO 시장 : 적응증 추정·동향 분석

  • 정의와 범위
  • 부문 대시보드
  • 세계의 재조합 단백질 치료제 CDMO 시장변수 분석
  • 세계의 재조합 단백질 치료제 CDMO 시장 규모와 동향 분석, 적응증별, 2018-2030년

제7장 재조합 단백질 치료제 CDMO 시장 : 유형, 소스, 적응증별 지역 추정·동향 분석

  • 지역 시장 대시보드
  • 세계의 지역 시장 스냅숏
  • 시장 규모와 예측 동향 분석, 2018-2030년
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카

제8장 경쟁 구도

  • 기업 분류
  • 재조합 단백질 치료제 CDMO 시장 점유율 분석, 2023년
  • Major Deals and Strategic Alliances Analysis
    • 전략 매핑
    • 확대
    • 파트너십
    • 인수
  • 벤더 구도
    • Key company market share analysis, 2023
    • Richter-Helm BioLogics
    • Lonza
    • Catalent, Inc
    • FUJIFILM Diosynth Biotechnologies
    • WuXi Biologics
    • Curia Global, Inc.
    • Batavia Biosciences BV
    • HALIX BV
    • BIOVIAN
    • Enzene Biosciences Ltd
LSH 24.03.25

Recombinant Protein Therapeutics CDMO Market Growth & Trends:

The global recombinant protein therapeutics CDMO market is expected to reach USD 52.0 billion by 2030 and is expected to expand at a CAGR of 13.95% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing technological innovations about the development of novel recombinant protein therapeutics and rising research and development for biologics are anticipated to influence the recombinant protein therapeutics CDMO industry positively. The development of novel recombinant protein therapeutics has observed significant advancements due to various technological innovations.

Recombinant proteins are bioengineered proteins produced by introducing the gene encoding the desired protein into a host cell, typically a microorganism or a mammalian cell, to express and produce the protein of interest. Several protein engineering platform technologies are currently employed to enhance the circulating half-life, targeting the precision and functionality of novel therapeutic protein drugs. These technologies also aim to boost production yield and ensure product purity.

Besides, the biopharmaceutical industry has witnessed significant growth, with an increasing number of companies investing in research and development of biologics, including recombinant proteins. This growth has been facilitated by advancements in manufacturing technologies, including adopting single-use bioreactors and other innovative production methods. For instance, in January 2024, Eurofins CDMO Alphora, Inc. announced the successful completion of its pilot-scale biologics development facility. With an expansive area of 3,300 square feet, this facility is exclusively dedicated to developing and scaling monoclonal antibodies (mAbs) and other therapeutic proteins derived from mammalian sources.

Moreover, the global increase in the prevalence of chronic and complex diseases, such as cancer, autoimmune disorders, & metabolic diseases, has increased the demand for innovative and effective therapeutic options. Recombinant protein therapeutics offer a diverse range of candidates to address these complex medical conditions. For instance, based on estimates from the American Cancer Society, it is projected that in 2023, there will be approximately 1,958,310 new cases of cancer and 609,820 cancer-related deaths in the U.S. Furthermore, according to a research article published by Oxford University, in June 2022, the number of approved and marketed antibody therapies reached 162, nearly half of which (42.6%) were being developed for the treatment of cancer.

In March 2023, the U.S. FDA granted accelerated clearance to Incyte Corporation's retifanlimab-dlwr for the treatment of adult patients with metastatic or recurrent, locally advanced Merkel Cell Carcinoma (MCC). Besides, biological therapy in cancer supports repairing, stimulating, or enhancing the immune response. Therefore, many pharmaceutical & biopharmaceutical companies are willing to invest in cancer-related novel treatments.Such advancements collectively aim to achieve a higher yield of quality products.

Recombinant Protein Therapeutics CDMO Market Report Highlights:

  • The others segment dominated the market in 2023. The segment growth is driven by increasing recombinant protein therapies as a safer option than plasma-derived products owing to the potential to reduce bloodborne transmission of infectious diseases
  • Based on the source, mammalian systems held the largest market share of 67.4% in 2023 attributed to an increase in the adoption of mammalian systems for sourcing recombinant proteins. Mammalian cell culture systems offer advantages in producing complex proteins with appropriate post-translational modifications, making them suitable for a wide range of therapeutic applications
  • Based on indication, the metabolic disorders segment held a market share of 21.8% in 2023. The segment is driven by a growing aging population, and robust demand for pharmaceutical industry, which has contributed to its prominence in this field
  • North America dominated the market with a share of 38.5% in 2023. The region has a strong R&D infrastructure and a robust biopharmaceutical industry, which has contributed to the market growth. Furthermore, the U.S. has a sophisticated and well-developed manufacturing infrastructure for biopharmaceuticals, including recombinant protein therapeutics

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's InternalL Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
    • 1.3.5. Details Of Primary Research
  • 1.4. Information Or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. Market Definitions
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives
    • 1.10.1. Objective - 1
    • 1.10.2. Objective - 2
    • 1.10.3. Objective - 3
    • 1.10.4. Objective - 4

Chapter 2. Chapter 2 Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Recombinant Protein Therapeutics CDMO Market: Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Recombinant Protein Therapeutics CDMO Market Dynamics
    • 3.2.1. Market Driver Impact Analysis
      • 3.2.1.1. Rising Adoption Of Biologics And Biosimilars
      • 3.2.1.2. Technological Innovations About The Development Of Novel Recombinant Protein Therapeutics
      • 3.2.1.3. Increasing Rate Of Clinical Research To Boost Demand For Recombinant Protein Therapeutics
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory Hurdles
      • 3.2.2.2. Challenges Related To Quality Control
  • 3.3. Recombinant Protein Therapeutics CDMO Market: Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
  • 3.4. Impact Of Covid-19 On Recombinant Protein Therapeutics CDMO Market
  • 3.5. Covid-19 Impact On Bioprocessing And Outsourcing
    • 3.5.1. Clinical Trial Supply & Logistics Services: Impact Of Covid-19
    • 3.5.2. Supply Chain
    • 3.5.3. Activities By CDMOs Increased Post-Covid-19 Pandemic, Supporting The Development Of Recombinant Protein Therapeutics
    • 3.5.4. Changes In The Long Term

Chapter 4. Recombinant Protein Therapeutics CDMO Market: Type Estimates & Trend Analysis

  • 4.1. Definitions and Scope
    • 4.1.1. Growth Hormones
    • 4.1.2. Interferons
    • 4.1.3. Vaccines
    • 4.1.4. Immunostimulating Agents
    • 4.1.5. Others
  • 4.2. Segment Dashboard
  • 4.3. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
  • 4.4. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
    • 4.4.1. Growth Hormones
      • 4.4.1.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 4.4.2. Interferons
      • 4.4.2.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 4.4.3. Vaccines
      • 4.4.3.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 4.4.4. Immunostimulating Agents
      • 4.4.4.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 4.4.5. Others
      • 4.4.5.1. Market Estimates and Forecast 2018 to 2030 (USD Million)

Chapter 5. Recombinant Protein Therapeutics CDMO Market: Source Estimates & Trend Analysis

  • 5.1. Definitions and Scope
    • 5.1.1. Mammalian Systems
    • 5.1.2. Microbial Systems
    • 5.1.3. Others
  • 5.2. Segment Dashboard
  • 5.3. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
  • 5.4. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Source, 2018 to 2030 (USD Million)
    • 5.4.1. Mammalian Systems
      • 5.4.1.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 5.4.2. Microbial Systems
      • 5.4.2.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 5.4.3. Others
      • 5.4.3.1. Market Estimates and Forecast 2018 to 2030 (USD Million)

Chapter 6. Recombinant Protein Therapeutics CDMO Market: Indication Estimates & Trend Analysis

  • 6.1. Definitions and Scope
    • 6.1.1. Oncology
    • 6.1.2. Infectious Diseases
    • 6.1.3. Immunological Disorders
    • 6.1.4. Metabolic Disorders
    • 6.1.5. Haematological Disorders
    • 6.1.6. Others
  • 6.2. Segment Dashboard
  • 6.3. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
  • 6.4. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
    • 6.4.1. Oncology
      • 6.4.1.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 6.4.2. Infectious Diseases
      • 6.4.2.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 6.4.3. Immunological Disorders
      • 6.4.3.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 6.4.4. Metabolic Disorders
      • 6.4.4.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 6.4.5. Haematological Disorders
      • 6.4.5.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Market Estimates and Forecast 2018 to 2030 (USD Million)

Chapter 7. Recombinant Protein Therapeutics CDMO Market: Regional Estimates & Trend Analysis by Type, Source, Indication

  • 7.1. Regional Market Dashboard
  • 7.2. Global Regional Market Snapshot
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Scenario
      • 7.4.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Scenario
      • 7.4.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Scenario
      • 7.5.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Scenario
      • 7.5.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Scenario
      • 7.5.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Scenario
      • 7.5.5.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Scenario
      • 7.5.6.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Scenario
      • 7.5.7.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Scenario
      • 7.5.8.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Competitive Scenario
      • 7.5.9.3. Regulatory Scenario
      • 7.5.9.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Scenario
      • 7.6.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Scenario
      • 7.6.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Scenario
      • 7.6.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Scenario
      • 7.6.5.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.6. Thailand
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Scenario
      • 7.6.6.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.7. South Korea
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Scenario
      • 7.6.7.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Scenario
      • 7.7.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.7.3. Mexico
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Scenario
      • 7.7.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.7.4. Argentina
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Scenario
      • 7.7.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Scenario
      • 7.8.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Scenario
      • 7.8.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Scenario
      • 7.8.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Scenario
      • 7.8.5.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Recombinant Protein Therapeutics CDMO Market Share Analysis, 2023
  • 8.3. Major Deals and Strategic Alliances Analysis
    • 8.3.1. Strategy Mapping
    • 8.3.2. Expansion
    • 8.3.3. Partnerships
    • 8.3.4. Acquisitions
  • 8.4. Vendor Landscape
    • 8.4.1. Key company market share analysis, 2023
    • 8.4.2. Richter-Helm BioLogics
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Lonza
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Catalent, Inc
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. FUJIFILM Diosynth Biotechnologies
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. WuXi Biologics
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Curia Global, Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Batavia Biosciences B.V.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. HALIX B.V.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. BIOVIAN
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. Enzene Biosciences Ltd
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제